行情

AKTX

AKTX

Akari
NASDAQ

实时行情|Nasdaq Last Sale

1.703
-0.030
-1.74%
交易中 12:39 10/22 EDT
开盘
1.730
昨收
1.734
最高
1.760
最低
1.700
成交量
6.23万
成交额
--
52周最高
9.20
52周最低
1.560
市值
2,692.40万
市盈率(TTM)
-1.9578
分时
5日
1月
3月
1年
5年

分析师评级

2位分析师的综合评级

强力推荐

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

AKTX 新闻

  • 午盘:财报好坏参半 美股维持窄幅震荡
  • 新浪美股.43分钟前
  • 美国财长姆努钦:已告诉FB目前发行Libra还不成熟
  • 新浪美股.1小时前
  • 因对阿根廷看走眼 富兰克林新兴市场基金被晨星降级
  • 新浪美股.1小时前
  • 美联储周二定期回购操作一个月来首次获得超额认购
  • 新浪美股.1小时前

更多

所属板块

生物技术和医学研究
+0.48%
制药与医学研究
+1.03%

热门股票

名称
价格
涨跌幅

AKTX 简况

Akari Therapeutics, Plc, formerly Celsus Therapeutics Plc, is a clinical-stage biopharmaceutical company. It is focused on the development and commercialization of treatments for a range of rare and orphan autoimmune and inflammatory diseases caused by dysregulation of complement component 5 (C5), including paroxysmal nocturnal hemoglobinuria, Guillain Barre syndrome and atypical Hemolytic Uremic Syndrome. Its lead drug, Coversin, a complement inhibitor, acts on complement C5, preventing release of C5a and formation of C5b-9. Coversin is a recombinant small protein derived from a protein discovered in the saliva of the Ornithodoros moubata tick, where it modulates the host immune system to allow the parasite to feed without alerting the host to its presence or provoking an immune response. It is conducting Phase Ib clinical trial of Coversin. It focuses on rare and orphan diseases, including disease states spanning hematology, nephrology, transplantation, neurology and ophthalmology.
展开

Webull提供Akari Therapeutics PLC (ADR)的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。